Small Pharmaceuticals
Market Cap
₹17,266 ₹17,266 Cr.
P/E
103.64
PEG
7.68
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes live if test-kit volume scales within existing capacity and assay commercialization supports demand without material tender or customer delays.

The bull path combines faster kit-volume growth with stronger realization; the bear path reflects volume shortfall, weaker pricing, delayed commercialization and underused capacity.

Key Ratios

Debt to Equity
Debt to Equity
0.35
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
5.60 %
Institutions
Institutions
17.88 %
Market cap
Market cap
17,266 Cr
No. of Shareholders
No. of Shareholders
2.34 L
OPM (%)
OPM (%)
-
PE
PE
103
Prom Holding
Prom Holding
41.29 %
ROCE (%)
ROCE (%)
17.36
ROE (%)
ROE (%)
14.25
Sales
Sales
1,445 Cr
  • Molbio Diagnostics
  • Poly Medicure
  • Dr. Lal Pathlabs
Last updated on 30 Sep 2026
  • Molbio Diagnostics makes its portable molecular testing platform, Truenat, with test kits and devices, plus handheld X-ray and digital pathology systems.
  • Its kits run on its devices in public tuberculosis centres in India and clinics in Africa and Southeast Asia. Entry into Europe and the US is underway.
  • It started as a molecular testing business and added radiology and digital pathology later. Test kits are now the core revenue.
  • Profit comes from recurring test kits for its portable molecular testing platform, Truenat, at about three-quarters of product revenue. Device sales and exports are lumpy.
  • It is the second globally endorsed technology for point-of-care tuberculosis testing. Its closed system keeps older devices running with no replacement cycle.
  • It is broadening beyond tuberculosis with no major new capex planned. Automation and a Bengaluru research centre are underway, alongside acquisitions and alliances.
  • The first listed quarter included about Rs57 crore of delayed Gulf exports. Management says quarters are non-linear and should be read for the full year.
  • Working capital stays high with elevated receivables and unresolved audit flags. Borrowings remain near cash levels.
  • FY27 depends on kit use from its installed devices and new assay sales. Management guides about 25% growth and 24-25% EBITDA margin for FY27.
  • Private equity fund, India Business Excellence Fund III, retains about 7% after two September sales.
  • Screening-test volumes by Q2FY27 results
    first volumes show whether the validated test converts to public demand.
  • European test rollout by Q2FY27 results
    rollout shows if single-sample testing displaces central batch testing.
  • Digital-pathology US ramp FY27 to FY28-29
    early hospital conversions show if losses stay within the $30m funding envelope.
  • Bengaluru research centre June 2028
    the integrated centre for 220 staff comes online.
  • Plant automation in Goa and Visakhapatnam deployment underway, no date stated
    automation adds headroom for twice FY26 revenue.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
926
52W Range
High
1687
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

6 Yes

Positive for this company

4 Neutral

Neutral for this company

3 No

Negative for this company

4 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Asset Break-Up - Geography Wise

Operational Metrics

    Select a Metric
    • Annual Sales Volume - Test Kits (No)

    Peer Comparison

    FAQs on Molbio Diagnostics Ltd. Business

    Molbio Diagnostics Limited, incorporated in 2000, is engaged in developing, manufacturing and commercializing point-of-care molecular diagnostic solutions. The company operates in the healthcare diagnostics segment, offering rapid testing solutions for infectious and non-communicable diseases through its Truenat platform.

    Molbio Diagnostics major competitors are Poly Medicure, Dr. Lal Pathlabs, Metropolis Health., Vijaya Diagnostic.
    Market Cap of Molbio Diagnostics is ₹17,460 Crs.
    While the median market cap of its peers are ₹15,660 Crs.

    Molbio Diagnostics seems to be less financially stable compared to its competitors.
    Altman Z score of Molbio Diagnostics is 12.87 and is ranked 4 out of its 5 competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release
    Investor Presentation Sep
    Conference Call Sep
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    []
    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material